Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.

Dubberke, Erik R; Orenstein, Robert; Khanna, Sahil; Guthmueller, Beth; Lee, Christine

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.

Dubberke, Erik R; Orenstein, Robert; Khanna, Sahil; Guthmueller, Beth; Lee, Christine.

Afiliação

Dubberke ER; Washington University School of Medicine, St. Louis, MO, USA. edubberk@wustl.edu.
Orenstein R; , 660 S Euclid, Box 8051, St. Louis, MO, 63110, USA. edubberk@wustl.edu.
Khanna S; Mayo Clinic Arizona, Phoenix, AZ, USA.
Guthmueller B; Mayo Clinic, Rochester, MN, USA.
Lee C; Rebiotix, Inc., Roseville, MN, USA.

Infect Dis Ther ; 12(2): 703-709, 2023 Feb.

Article em En | MEDLINE | ID: mdl-36544075

Palavras-chave

Clostridioides difficile; Clostridium difficile; Live biotherapeutic product; Microbiota; RBX2660; Recurrent CDI

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline Idioma: En Ano de publicação: 2023 Tipo de documento: Article